bioTheranostics Expands Its PRÉCIS Biomarker Profiles and Strengthens Its Industry-Leading Solution for Metastatic Cancer

SAN DIEGO--(BUSINESS WIRE)--bioTheranostics, Inc., provider of solutions for metastatic cancer through the development of innovative oncology diagnostic tests, today announced that its PRÉCISSM Precision Medicine biomarker profiles for non-small cell lung and colorectal cancers have been expanded. The profiles now include 13 non-small cell lung and seven colorectal cancer clinically relevant tumor biomarkers, many of which also may be used in other cancers such as melanoma.